Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213455 | 0.87 | HTT (0.45) | TSHRKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27813654 | 0.84 | CA2 (0.50) | CA2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9950354 | 0.83 | CA2 (0.52) | CA2CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL30477927 | 0.83 | CA2 (0.52) | CA2CYP1A2CYP3A4CYP2D6BLM | |
| SCHEMBL3765408 | 0.80 | TSHR (0.50) | TSHRALDH1A1SMN1; SMN2NPC1HTT | |
| SCHEMBL29024815 | 0.78 | TSHR (0.48) | TSHRSMN1; SMN2NPC1POLBMEN1 | |
| SCHEMBL27792356 | 0.78 | CA2 (0.53) | CA2TSHRCYP1A2CYP3A4ATM | |
| SCHEMBL6042848 | 0.76 | TSHR (0.50) | TSHRCYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL4586654 | 0.76 | TSHR (0.54) | TSHRKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL3196647 | 0.76 | TSHR (0.54) | CA2TSHRKDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389411-B2 | Pharmaceutical composition, containing NM23 activator, for inhibiting cancer metastasis | EWHA University—Industry Collaboration Foundation (KR) | 2022-07-19 | — | — | US | disclosed |
| US-20200078319-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2020-03-12 | — | — | US | disclosed |
| EP-3616692-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | Ewha University-Industry Collaboration Foundation (KR) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078319-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | NME1, NTPCR, NME2 | CA2 562/4885TSHR 4602/4885CYP1A2 4727/4885 |
| US-11389411-B2 | Pharmaceutical composition, containing NM23 activator, for inhibiting cancer metastasis | NME1, NTPCR, NME2 | CA2 562/4885TSHR 4602/4885CYP1A2 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.